Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Cadrenal Therapeutics, Inc.
Via Business Wire
Tickers CVKD
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
From Cadrenal Therapeutics, Inc.
Via Business Wire
Tickers CVKD
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
From Cadrenal Therapeutics, Inc.
Via Business Wire
Tickers CVKD
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
Tickers CVKD
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
From Cadrenal Therapeutics, Inc.
Via Business Wire
Tickers CVKD
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
From Cadrenal Therapeutics, Inc.
Via Business Wire
Tickers CVKD
Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq
From Cadrenal Therapeutics, Inc.
Via Business Wire
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
From Cadrenal Therapeutics, Inc.
Via Business Wire
Tickers CVKD
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
From Cadrenal Therapeutics, Inc.
Via Business Wire
Tickers CVKD
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
From Cadrenal Therapeutics, Inc.
Via Business Wire
Tickers CVKD
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
From Cadrenal Therapeutics, Inc.
Via Business Wire
Tickers CVKD
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
From Cadrenal Therapeutics, Inc.
Via Business Wire
Tickers CVKD
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
Tickers CVKD
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
From Cadrenal Therapeutics, Inc.
Via Business Wire
Tickers CVKD
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.